RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care

 


  • RenovoRx Inc RNXT announced interim data in the Phase 3 open-label TIGeR-PaC clinical trial investigating the company's first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (LAPC).

  • The interim analysis suggests a 6-month potential improvement in median overall survival with RenovoGem.

  • The study compares treatment with RenovoTAMP versus standard-of-care systemic intravenous administration of gemcitabine and nab-paclitaxel, which has a seven-week survival benefit and a $1 billion addressable market.

  • Related: RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic Cancer.

  • This first-of-two interim analysis indicates that the TIGeR-PaC study is on track to demonstrate increased lifespan for patients treated with RenovoGem for LAPC. 

  • In this interim analysis, the control and treatment arms demonstrated divergence in median overall survival for patients. 

  • Twenty-three patients were randomized to the intra-arterial gemcitabine (RenovoGem investigational treatment) arm and 22 to the continuation of IV gemcitabine and nab-paclitaxel (control or standard of care) arm. 

  • There were an equal number of primary events, 13 in each arm.

  • The median overall survival in the IV gemcitabine and nab-paclitaxel control arm was ten months versus 16 months in the intra-arterial RenovoGem arm. 

  • Observed a positive trend in median overall survival by 24 weeks. In this interim analysis, the statistical significance was not reached to stop the study early.

  • Price Action: RNXT shares are up 0.33% at $4.92 on the last check Wednesday.


  •  

 

 

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!